MAPT and dementia: While a number of biomarkers have been found to be inaccurate in distinguishing AD from non-AD dementia in clinical applications, researchers have recently demonstrated that blood levels of p-tau181 can distinguish AD from other neurodegenerative illnesses, with results consistent with p-tau protein in CSF (Simrén et al., 2021).